AR030211A1 - Compuestos derivados de amino-pirazol, composicion farmaceutica que lo comprende y su uso en el tratamiento de enfermedades mediadas por la actividad de la quinasa proteinica - Google Patents

Compuestos derivados de amino-pirazol, composicion farmaceutica que lo comprende y su uso en el tratamiento de enfermedades mediadas por la actividad de la quinasa proteinica

Info

Publication number
AR030211A1
AR030211A1 ARP010101823A ARP010101823A AR030211A1 AR 030211 A1 AR030211 A1 AR 030211A1 AR P010101823 A ARP010101823 A AR P010101823A AR P010101823 A ARP010101823 A AR P010101823A AR 030211 A1 AR030211 A1 AR 030211A1
Authority
AR
Argentina
Prior art keywords
compounds
substituted
formula
activity
unsubstituted
Prior art date
Application number
ARP010101823A
Other languages
English (en)
Inventor
Siegfried Reich
Michael Wallace
Original Assignee
Agouron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharma filed Critical Agouron Pharma
Publication of AR030211A1 publication Critical patent/AR030211A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos derivados de amino-pirazol de formula (1) donde R1 es un alquilo, arilo, heteroarilo, cicloalquilo o heterocicloalquilo sustituido o insustituido; R2 es un heteroarilo o heterocicloalquilo sustituido o insustituido; y R3 es hidrogeno, fluor, cloro, bromo, yodo o un alquilo C1-8 sustituido o insustituido, o R2 y R3 juntos forman un anillo arilo, heteroarilo, cicloalquilo o heterocicloalquilo de 5 miembros sustituido o insustituido; o una sal farmacéuticamente aceptable de un compuesto de la formula (1) o una prodroga farmacéuticamente aceptable de un compuesto de la formula (1); o un metabolito farmacéuticamente activo de un compuesto de la formula (1) o una sal farmacéuticamente aceptable de dicho metabolito. Dichos compuestos modulan y/o inhiben la actividad de quinasas proteínicas. Estos compuestos y las composiciones farmacéuticas que los contienen son capaces de mediar y/o inhibir la actividad de quinasas dependientes de la ciclina, por tanto modulando y/o inhibiendo la proliferacion celular indeseada. El invento está también dirigido al uso terapéutico o profiláctico de composiciones farmacéuticas que contienen tales compuestos, y a métodos de tratamiento de cáncer, además de otros estados de enfermedad asociados con angiogénesis indeseada y/o proliferacion celular, tal como retinopatía diabética, glaucoma neovascular, artritis reumática y psoriasis, administrando cantidades eficaces de tales compuestos.
ARP010101823A 2000-04-18 2001-04-18 Compuestos derivados de amino-pirazol, composicion farmaceutica que lo comprende y su uso en el tratamiento de enfermedades mediadas por la actividad de la quinasa proteinica AR030211A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19786200P 2000-04-18 2000-04-18

Publications (1)

Publication Number Publication Date
AR030211A1 true AR030211A1 (es) 2003-08-13

Family

ID=22731040

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010101823A AR030211A1 (es) 2000-04-18 2001-04-18 Compuestos derivados de amino-pirazol, composicion farmaceutica que lo comprende y su uso en el tratamiento de enfermedades mediadas por la actividad de la quinasa proteinica

Country Status (13)

Country Link
US (1) US6462069B2 (es)
EP (1) EP1274706A1 (es)
JP (1) JP2004501083A (es)
AR (1) AR030211A1 (es)
AU (1) AU2001249865A1 (es)
BR (1) BR0110302A (es)
CA (1) CA2398446A1 (es)
GT (1) GT200100061A (es)
MX (1) MXPA02010222A (es)
PA (1) PA8515701A1 (es)
PE (1) PE20020226A1 (es)
SV (1) SV2002000376A (es)
WO (1) WO2001079198A1 (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020150921A1 (en) * 1996-02-09 2002-10-17 Francis Barany Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
CZ301750B6 (cs) 1999-12-24 2010-06-09 Aventis Pharma Limited Bicyklický pyrrolový derivát, jeho použití pri výrobe léciva, farmaceutická kompozice tento derivát obsahující a pro použití pri lécení
HUP0302669A3 (en) * 2000-08-31 2004-03-29 Pfizer Prod Inc Pyrazole derivatives and pharmaceutical compositions containing them for treating diseases comprising abnormal cell growth and neurodegenerative diseases
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
MXPA03002294A (es) 2000-09-15 2005-09-08 Vertex Pharma Compuestos de pirazol utiles como inhibidores de proteina cinasa.
EP1345922B1 (en) 2000-12-21 2006-05-31 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6756374B2 (en) 2001-01-22 2004-06-29 Hoffmann-La Roche Inc. Diaminothiazoles having antiproliferative activity
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
WO2003097609A1 (en) * 2002-05-15 2003-11-27 Janssen Pharmaceutica N.V. N-substituted tricyclic 3-aminopyrazoles as pdfg receptor inhibitors
EP1739087A1 (en) * 2002-08-02 2007-01-03 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of gsk-3
JP4733388B2 (ja) * 2002-08-02 2011-07-27 バーテックス ファーマシューティカルズ インコーポレイテッド Ｇｓｋ−３のインヒビターとして有用なピラゾール組成物
US7157455B2 (en) 2003-02-10 2007-01-02 Hoffmann-La Roche Inc. 4-Aminopyrimidine-5-one derivatives
BRPI0407618A (pt) * 2003-02-21 2006-02-21 Pfizer derivados de tiazole amino substituidos com cicloalquilo contendo n e composições farmacêuticas para inibição da proliferação celular e métodos para a sua utilização
JP2006519234A (ja) 2003-02-27 2006-08-24 スミスクライン ビーチャム コーポレーション 新規化合物
FR2854159B1 (fr) * 2003-04-25 2008-01-11 Aventis Pharma Sa Nouveaux derives de l'indole, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de kdr
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
US20050032869A1 (en) * 2003-07-08 2005-02-10 Pharmacia Italia S.P.A. Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
KR101204247B1 (ko) * 2003-07-22 2012-11-22 아스텍스 테라퓨틱스 리미티드 3,4-이치환된 1ｈ-피라졸 화합물 및 그의 시클린 의존성키나제 (ｃｄｋ) 및 글리코겐 합성효소 키나제-3(ｇｓｋ-3) 조정제로서 용도
WO2005009435A1 (en) * 2003-07-25 2005-02-03 Pfizer Inc. Aminopyrazole compounds and use as chk1 inhibitors
WO2005049579A2 (en) * 2003-11-13 2005-06-02 Janssen Pharmaceutica N.V. Immobilized n-substituted tricyclic 3-aminopyrazoles for the identification of biomolecular targets
GB0326601D0 (en) * 2003-11-14 2003-12-17 Novartis Ag Organic compounds
GB2410947B (en) * 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
US7211576B2 (en) 2004-04-20 2007-05-01 Hoffmann-La Roche Inc. Diaminothiazoles
EP1742921A2 (en) * 2004-04-21 2007-01-17 AstraZeneca AB Pyrazole derivatives useful for the treatment of cancer
US20060035920A1 (en) * 2004-05-28 2006-02-16 Millennium Pharmaceuticals, Inc. Chk-1 inhibitors
US20070254877A1 (en) * 2004-06-02 2007-11-01 Takada Pharmaceutical Company Limited Indole Derivative and Use for Treatment of Cancer
US7405220B2 (en) 2004-06-09 2008-07-29 Hoffmann-La Roche Inc. Pyrazolopyrimidines
US7423051B2 (en) 2004-07-15 2008-09-09 Hoffmann-La Roche Inc. 2,6-diaminopyridine derivatives
US7423053B2 (en) 2004-07-15 2008-09-09 Hoffmann-La Roche Inc. 4-Aminothiazole derivatives
JP2008520713A (ja) * 2004-11-17 2008-06-19 ミイカナ セラピューティクス インコーポレイテッド キナーゼ阻害剤
AU2005321091B2 (en) 2004-12-30 2012-04-12 Astex Therapeutics Limited Pyrazole compounds that modulate the activity of CDK, GSK and Aurora kinases
WO2006070198A1 (en) * 2004-12-30 2006-07-06 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
WO2006101454A1 (en) * 2005-03-21 2006-09-28 S*Bio Pte Ltd Benzothiophene derivatives: preparation and pharmaceutical applications
GB0514501D0 (en) * 2005-07-14 2005-08-24 Cambridge Lab Ireland Ltd Pharmaceutical compounds
GB0516168D0 (en) * 2005-08-05 2005-09-14 Cambridge Lab Ireland Ltd Pharmaceutical compounds
ES2535854T3 (es) * 2005-09-30 2015-05-18 Miikana Therapeutics, Inc. Compuestos de pirazol sustituidos
US7705009B2 (en) 2005-11-22 2010-04-27 Hoffman-La Roche Inc. 4-aminopyrimidine-5-thione derivatives
US8399442B2 (en) 2005-12-30 2013-03-19 Astex Therapeutics Limited Pharmaceutical compounds
WO2007089044A1 (ja) * 2006-02-03 2007-08-09 Sumitomo Chemical Company, Limited 芳香族化合物の製造方法
WO2008001115A2 (en) 2006-06-29 2008-01-03 Astex Therapeutics Limited Pharmaceutical combinations of 1-cyclopropyl-3- [3- (5-m0rphoolin-4-ylmethyl-1h-benzoimidazol-2-yl) -lh-1-pyrazol- 4-yl] -urea
JP2010529193A (ja) * 2007-06-11 2010-08-26 ミイカナ セラピューティクス インコーポレイテッド 置換ピラゾール化合物
AR071717A1 (es) 2008-05-13 2010-07-07 Array Biopharma Inc Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
GB0810857D0 (en) * 2008-06-13 2008-07-23 Cambridge Lab Ireland Ltd Pharmaceutical compounds
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
GB2462611A (en) * 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
GB2463452A (en) * 2008-09-08 2010-03-17 Cambridge Lab Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof
GB2463451A (en) 2008-09-08 2010-03-17 Cambridge Lab 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia
GB2463283A (en) * 2008-09-08 2010-03-10 Cambridge Lab 3,11b-cis-dihydrotetrabenazine for use in treating asthma
CN103408540B (zh) * 2013-08-22 2016-05-18 中国药科大学 2-唑环取代噻吩类plk1抑制剂及其用途及其用途
CN108690006B (zh) * 2017-04-12 2022-02-18 中国药科大学 一类化合物及其在抗aml药物中的用途
JP7302794B2 (ja) 2018-02-07 2023-07-04 コリア リサーチ インスティチュート オブ ケミカル テクノロジー Ｔｎｉｋを阻害するための化合物及びその医学的使用
CN110835334B (zh) * 2018-08-16 2022-10-18 中国药科大学 吲哚取代唑类化合物及其用途
TW202313588A (zh) 2021-05-27 2023-04-01 美商無界生物公司 檢測點激酶１（ｃｈｋ１）抑制劑及其用途
WO2024118564A1 (en) * 2022-11-29 2024-06-06 Boundless Bio, Inc. Checkpoint kinase 1 (chk1) inhibitors and uses thereof

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE273062C (de) 1912-04-19 1914-04-20 Deylen Sohn Firma Vorrichtung zum Schränken von Plattenzündspänen
CH575397A5 (es) 1971-11-09 1976-05-14 Basf Ag
EP0218728A1 (en) 1985-04-03 1987-04-22 Yamanouchi Pharmaceutical Co. Ltd. Phenylene derivatives
JPH083564B2 (ja) 1986-07-25 1996-01-17 三菱化学株式会社 偏光フィルム
DD273062A1 (de) 1988-06-14 1989-11-01 Fahlberg List Veb Verfahren zur herstellung von hydroxybenzoesaeure(chinoxalin-2-ylmethyl)-ethern und -estern
CA1330079C (en) * 1988-10-13 1994-06-07 Michihiko Tsujitani Pyrrolo (3,2-e)pyrazolo(1,5-a)pyrimidine derivative and medicine comprising the same
CA2102780C (en) 1991-05-10 2007-01-09 Alfred P. Spada Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
CA2130196A1 (en) 1992-03-24 1993-09-30 Jose Luis Castro Pineiro Benzodiazepine derivatives
US5612360A (en) 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
AU5704594A (en) 1992-12-18 1994-07-19 Wellcome Foundation Limited, The Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors
US5625031A (en) 1994-02-08 1997-04-29 Bristol-Myers Squibb Company Peptide inhibitors of the p33cdk2 and p34cdc2 cell cycle regulatory kinases and human papillomavirus E7 oncoprotein
US5631156A (en) 1994-06-21 1997-05-20 The University Of Michigan DNA encoding and 18 KD CDK6 inhibiting protein
DE69532817T2 (de) * 1994-11-10 2005-01-13 Millenium Pharmaceuticals, Inc., Cambridge Verwendung von pyrazole verbindungen zur behandlung von glomerulonephritis, krebs, atherosklerose oder restenose
KR19980701879A (ko) 1995-02-02 1998-06-25 피터 기딩스 5-히드록시트립타민 수용체 길항제로서의 인돌 유도체
US5710173A (en) 1995-06-07 1998-01-20 Sugen, Inc. Thienyl compounds for inhibition of cell proliferative disorders
AU6526896A (en) 1995-07-22 1997-02-18 Rhone-Poulenc Rorer Limited Substituted aromatic compounds and their pharmaceutical use
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
US5705499A (en) 1995-10-06 1998-01-06 Boehringer Ingelheim Pharmaceuticals, Inc. 8-arylalkyl- and 8-arylheteroalkyl-5,11-dihydro-6H-dipyrido 3,2-B:2',3'-e! 1!diazepines and their use in the treatment of HIV-1 infection
US5733920A (en) 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
US5760028A (en) 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
US6495526B2 (en) 1996-01-23 2002-12-17 Gpc Biotech, Inc. Inhibitors of cell-cycle progression and uses related thereto
WO1997034876A1 (en) 1996-03-15 1997-09-25 Zeneca Limited Cinnoline derivatives and use as medicine
GB9608435D0 (en) 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
US5849733A (en) 1996-05-10 1998-12-15 Bristol-Myers Squibb Co. 2-thio or 2-oxo flavopiridol analogs
EP0816357B1 (en) 1996-06-27 2002-01-09 Pfizer Inc. Substituted indazole derivatives
FR2750862B1 (fr) 1996-07-12 1998-10-16 Dupin Jean Pierre Utilisation d'heterocycles diazotes fusionnes avec un systeme aromatique ou heteroaromatique pour le traitement des maladies thrombo-emboliques
US5821243A (en) 1996-07-22 1998-10-13 Viropharma Incorporated Compounds compositions and methods for treating influenza
BR9712005A (pt) 1996-09-04 1999-08-24 Pfizer Derivados de indazol e seus usos como inibidores de fosfodiesterase (pde) tipo IV e produ-Æo do fator de necrose de tumor (tnf)
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
GB9621757D0 (en) 1996-10-18 1996-12-11 Ciba Geigy Ag Phenyl-substituted bicyclic heterocyclyl derivatives and their use
WO1998033798A2 (en) 1997-02-05 1998-08-06 Warner Lambert Company Pyrido[2,3-d]pyrimidines and 4-amino-pyrimidines as inhibitors of cell proliferation
AU6230098A (en) 1997-02-27 1998-09-18 Tanabe Seiyaku Co., Ltd. Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitors
CA2294244A1 (en) 1997-07-12 1999-01-21 Cancer Research Campaign Technology Limited Cyclin dependent kinase inhibiting purine derivatives
GB9716324D0 (en) 1997-08-01 1997-10-08 Mead Corp Packaging machine and method of carton set up
FR2767827A1 (fr) 1997-09-03 1999-02-26 Adir Nouveaux derives de l'indole et de l'indazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
AU9691198A (en) 1997-10-06 1999-04-27 Basf Aktiengesellschaft Indeno{1,2-c}-, naphtho{1,2-c}- and benzo{6,7}cyclohepta{1,2-c}pyrazole derivatives
BR9815200A (pt) 1997-10-27 2001-10-16 Agouron Pharma Composto, composição farmacêutica e método de tratamento de uma doença ou distúrbio mediado pela inibição de cdk4 ou um complexo de cdk4/ciclina
IL135900A0 (en) 1997-11-04 2001-05-20 Pfizer Prod Inc Indazole bioisostere replacement of catechol in therapeuticaly active compounds
NZ503995A (en) 1997-11-04 2003-02-28 Pfizer Prod Inc Indazole compounds, and pharmaceutical compositions and uses thereof, based on indazole bioisostere replacement of catechol in PDE4 inhibitors
US6040321A (en) 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
HUP0100931A3 (en) 1998-02-26 2002-08-28 Aventis Pharma Inc 6,9-disubstituted 2-[trans-(-aminocyclohexyl)amino]purines and pharmaceutical compositions containing them
US6479487B1 (en) 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
EA003603B1 (ru) 1998-02-27 2003-06-26 Пфайзер Продактс Инк. N-[(замещенное пятичленное ди- или триазадиненасыщенное кольцо) карбонил] гуанидиновые производные для лечения ишемии
JP4665239B2 (ja) 1998-04-21 2011-04-06 アゲンニクス アーゲー 抗癌剤および抗増殖性薬剤としての５−アミノインデノ［１，２−ｃ］ピラゾール−４−オン
ATE288904T1 (de) 1998-06-18 2005-02-15 Bristol Myers Squibb Co Durch kohlenstoff substituierte aminothiazole als inhibitoren von zyclin-abhägigen kinasen
UA72749C2 (en) 1998-09-29 2005-04-15 White Holdings Corp Substituted 3-cyanoquinolines, a method for the preparation thereof (variants), pharmaceutical composition based thereon, a method for the treatment, inhibiting the growth or elimination of neoplasms and a method for the treatment, inhibiting progressing or elimination of polycystic kidney disease using them
EP1189609A4 (en) * 1999-05-03 2002-10-30 Smithkline Beecham Corp CXCR-4 RECEPTOR ANTAGONISTS AND THROMBOPOIETIN MIMETIKA

Also Published As

Publication number Publication date
WO2001079198A9 (en) 2002-05-16
WO2001079198A1 (en) 2001-10-25
CA2398446A1 (en) 2001-10-25
JP2004501083A (ja) 2004-01-15
PA8515701A1 (es) 2002-02-21
WO2001079198B1 (en) 2002-06-13
US20020006952A1 (en) 2002-01-17
MXPA02010222A (es) 2003-05-23
GT200100061A (es) 2002-03-14
AU2001249865A1 (en) 2001-10-30
PE20020226A1 (es) 2002-04-02
EP1274706A1 (en) 2003-01-15
BR0110302A (pt) 2003-01-14
US6462069B2 (en) 2002-10-08
SV2002000376A (es) 2002-12-02

Similar Documents

Publication Publication Date Title
AR030211A1 (es) Compuestos derivados de amino-pirazol, composicion farmaceutica que lo comprende y su uso en el tratamiento de enfermedades mediadas por la actividad de la quinasa proteinica
MA58004B1 (fr) Dérivés de pyrazolyle utiles en tant qu'agents anticancéreux
AR035554A1 (es) Compuesto derivado de indazol, composicion farmaceutica que lo comprende y su uso en la fabricacion de medicamentos para modular la actividad de quinasa proteina.
AR032438A1 (es) Compuesto derivado de indazol, composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento para tratar enfermedades proteinquinasa dependientes
ECSP066335A (es) Compuestos de indazol 3,5-disustituidos, composiciones farmacéuticas y métodos para intervenir en o inhibir la proliferación celular
AR042510A1 (es) Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas y procedimientos para su uso
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
EA200401613A1 (ru) Лекарственное средство для лечения рака
GT200100014A (es) Compuestos de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo.
EA200200708A1 (ru) Производные бензазола и их применение в качестве модуляторов jnk
BRPI0114704B8 (pt) composto de imidazol fundido a arila ou heteroarila, suas composições farmacêuticas, bem como seu uso
AR035374A1 (es) Un derivado de fenilacetamido-pirazol, su uso, un procedimiento para su preparacion, una composicion farmaceutica que lo comprende, un kit que comprende dicho derivado o composicion, un metodo para tratar desordenes proliferativos celularaes asociados con una actividad quinasa dependiente de ciclo c
EP2968233A1 (en) Histone deacetylase inhibitors and compositions and methods of use thereof
EA200001061A1 (ru) Фармацевтическая композиция
AR032763A1 (es) Compuestos pirazol-tiazol, composicion farmaceutica que lo contiene, y el uso de dicho compuesto en la fabricacion de medicamentos para inhibir quinasas ciclino-dependientes
WO2016179554A1 (en) Histone deacetylase inhibitors and compositions and methods of use thereof
CO2023002940A2 (es) Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos
AR101566A2 (es) Composición farmacéutica de compuestos heterobicíclicos que contienen nitrógeno
DE60011110D1 (de) Pharmazeutisch wirksame sulfonyl hydrazid-derivate
DK0780125T3 (da) Anvendelse af hydantoinderivater til fremstilling af et lægemiddel til behandling af sygdomme associeret med tilstedeværelse af aktivt oxygen og frie radikaler
DK1242406T3 (da) Hidtil ukendte forbindelser
MX9405111A (es) Nuevos derivados de (1-fenil-1-heterociclil)metanol y(1-fenil-1-heterociclil-metilamina).
CA2366829A1 (fr) Nouveaux derives de morpholine, procede pour leur preparation et compositions pharmaceutiques les contenant
AR055108A1 (es) Derivados de fenilpiridina, su obtencion y su utilizacion en composiciones farmaceuticas para el tratamiento del cancer.
GT200100170A (es) Compuestos con nucleos heterocicliclo-hidroximino-fluoreno y las composiciones farmaceuticas para la inhibicion delasproteinas quinasas y los metodos para su uso.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal